Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 3/2017

01-07-2017 | REVIEW

The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis

Authors: Jun-Long Song, Chuang Chen, Jing-Ping Yuan, Sheng-Rong Sun

Published in: Familial Cancer | Issue 3/2017

Login to get access

Abstract

Whether a positive family history of breast cancer or ovarian cancer (FHBOC) would affect the prognosis of breast cancer is still up for debate and further study. This meta-analysis was performed to clarify this issue. We reviewed two databases (PubMed and CNKI) for research articles published at any time from the inception of these databases to April 1, 2016 for articles detecting the impact of FHBOC on the prognosis of breast cancer. A meta-analysis was conducted to generated combined hazard ratios (HR) with 95% confidence intervals (CI) for overall survival (OS) and breast cancer-specific survival (BCSS). Eighteen studies were included in our qualitative analysis, with 15 studies ultimately part of the quantitative analysis. The pooled results demonstrated that a positive FHBOC was associated with better OS (0.89, 95% CI 0.83–0.95) and BCSS (0.90, 95% CI 0.82–0.99). In subgroup analyses, several subgroups (maximally adjusted studies, population based studies, high quality studies, family history of breast cancer, studies from Europe, studies from Asia, 1 affected relative, or tumor size > 2 cm), a positive first-degree FHBOC was associated with better prognosis of breast cancer. Notably, for those patients who underwent breast-conserving surgery, first-degree FHBOC was not a risk factor for OS (HR 1.08, 95% CI 0.53–2.21). Our meta-analysis demonstrated that a first-degree FHBOC was associated with better OS and BCSS in patients with breast cancer. These findings support that clinical management should not differ between women with and without FHBOC.
Literature
1.
Slattery ML, Kerber RA (1993) A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 270:1563–1568PubMedCrossRef
2.
Pharoah PD, Day NE, Duffy S et al (1997) Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 71:800–809PubMedCrossRef
3.
Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17–22PubMedCrossRef
4.
Hemminki K, Ji J, Forsti A (2007) Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res 67:868–870PubMedCrossRef
5.
Shahedi K, Emanuelsson M, Wiklund F, Gronberg H (2006) High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma. Cancer 106:1237–1242PubMedCrossRef
6.
Malone KE, Daling JR, Weiss NS et al (1996) Family history and survival of young women with invasive breast carcinoma. Cancer 78:1417–1425PubMedCrossRef
7.
Malone KE, Daling JR, Doody DR et al (2011) Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer. Cancer Epidemiol Biomark Prev 20:2560–2571CrossRef
8.
Gonzalez-Angulo AM, Broglio K, Kau SW et al (2005) Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 103:2466–2472PubMedCrossRef
9.
Omar MA, Motala AA, Seedat MA and Pirie F, (1996) The significance of a positive family history in South African Indians with non-insulin-dependent diabetes (NIDDM). Diabetes Res Clin Pract 34:S13–S16PubMedCrossRef
10.
Russo A, Herd-Smith A, Gestri D et al (2002) Does family history influence survival in breast cancer cases? Int J Cancer 99:427–430PubMedCrossRef
11.
Seynaeve C, Verhoog LC, van de Bosch LM et al (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40:1150–1158PubMedCrossRef
12.
Thalib L, Wedren S, Granath F et al (2004) Breast cancer prognosis in relation to family history of breast and ovarian cancer. Br J Cancer 90:1378–1381PubMedPubMedCentralCrossRef
13.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012PubMedCrossRef
14.
Deeks JJ, Dinnes J, D’Amico R et al (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7:1–173CrossRef
15.
16.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef
17.
18.
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRef
19.
Vlastos G, Mirza NQ, Meric F et al (2002) Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol 9:912–919PubMedCrossRef
20.
Turkoz FP, Solak M, Aksoy S et al (2012) Association between family history and clinicopathologic characteristics in 1987 breast cancer patients: single institution experience from Turkey. J BUON 17:649–657PubMed
21.
Slattery ML, Berry TD, Kerber RA (1993) Is survival among women diagnosed with breast cancer influenced by family history of breast cancer? Epidemiology 4:543–548PubMedCrossRef
22.
Schouten LJ, Hupperets PS, Jager JJ et al (1997) Prognostic significance of etiological risk factors in early breast cancer. Breast Cancer Res Treat 43:217–223PubMedCrossRef
23.
Melvin JC, Wulaningsih W and Hana Z et al., (2016) Family history of breast cancer and its association with disease severity and mortality. Cancer Med 5:942–49PubMedPubMedCentralCrossRef
24.
Chen LM, Mundt AJ, Powers C, Halpern HJ, Weichselbaum RR (1996) Significance of family history in breast cancer treated with breast conservation therapy. Breast J 2:238–245CrossRef
25.
Kinoshita T, Fukutomi T, Iwamoto E, Akashi-Tanaka S (2004) Prognosis of breast cancer patients with familial history classified according to their menopausal status. Breast J 10:218–222PubMedCrossRef
26.
Kharazmi E, Forsti A, Sundquist K, Hemminki K (2016) Survival in familial and non-familial breast cancer by age and stage at diagnosis. Eur J Cancer 52:10–18PubMedCrossRef
27.
Jobsen JJ, van der Palen J, Brinkhuis M et al (2016) Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer. Acta Oncol 55:449–454PubMedCrossRef
28.
Harris EE, Schultz DJ, Peters CA, Solin LJ (2000) Relationship of family history and outcome after breast conservation therapy in women with ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 48:933–941PubMedCrossRef
29.
Chang ET, Milne RL, Phillips KA et al (2009) Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the breast cancer family registry. Breast Cancer Res Treat 117:167–176PubMedCrossRef
30.
Chabner E, Nixon A, Gelman R et al (1998) Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 16:2045–2051PubMedCrossRef
31.
Cao AY, He M, DI GH et al (2011) Influence of a family history of breast and/or ovarian cancer on breast cancer outcomes. Exp Ther Med 2: 917–23PubMedPubMedCentral
32.
Yuan ZY, Wang SS, Zhu MQ et al (2008) [Clinical characteristics and prognosis of different subtypes of breast cancer]. Zhonghua Zhong Liu Za Zhi 30:456–61
33.
34.
Albano WA, Recabaren JA, Lynch HT et al (1982) Natural history of hereditary cancer of the breast and colon. Cancer 50:360–363PubMedCrossRef
35.
Fukutomi T, Kobayashi Y, Nanasawa T et al (1993) A clinicopathological analysis of breast cancer in patients with a family history. Surg Today 23:849–854PubMedCrossRef
36.
Moller P, Evans DG, Reis MM et al (2007) Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer 121:1017–1020PubMedCrossRef
37.
Maurice A, Evans DG, Shenton A et al (2006) Screening younger women with a family history of breast cancer–does early detection improve outcome? Eur J Cancer 42:1385–1390PubMedCrossRef
38.
Margolin S, Johansson H, Rutqvist LE et al (2006) Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. Fam Cancer 5:309–321PubMedCrossRef
39.
Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18:107S-112 S
40.
Armes JE, Trute L, White D et al (1999) Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59:2011–2017PubMed
41.
Brekelmans CT, Voogd AC, Botke G et al (1999) Family history of breast cancer and local recurrence after breast-conserving therapy. The Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Eur J Cancer 35:620–626PubMedCrossRef
42.
Zhong Q, Peng HL, Zhao X et al (2015) Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res 21:211–220PubMedCrossRef
43.
Malone KE, Daling JR, Thompson JD et al (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279:922–929PubMedCrossRef
44.
Loman N, Bladstrom A, Johannsson O et al (2003) Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 5:R175–R186PubMedPubMedCentralCrossRef
45.
Sapkota Y (2014) Germline DNA variations in breast cancer predisposition and prognosis: a systematic review of the literature. Cytogenet Genome Res 144:77–91PubMedCrossRef
Metadata
Title
The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis
Authors
Jun-Long Song
Chuang Chen
Jing-Ping Yuan
Sheng-Rong Sun
Publication date
01-07-2017
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-9969-x

Other articles of this Issue 3/2017

Familial Cancer 3/2017 Go to the issue

Short Communication

A lesson from a reported pathogenic variant in Peutz-Jeghers syndrome: a case report

Original Article

Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients

Original Article

Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?

Original Article

Biallelic BRCA2 mutations in two black South African children with Fanconi anaemia

Short Communication

Embryonal rhabdomyosarcoma in a patient with a heterozygous frameshift variant in the DICER1 gene and additional manifestations of the DICER1 syndrome

Short Communication

ATM mutations for surgeons
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits